Guosheng Capital
国生资本
elsewhere's coverage of Guosheng Capital (国生资本) is thin — no profile of the fund itself, but it surfaces twice in 2025-2026 deal announcements, always in life sciences. Per Qiming Venture Partners, it is the Chengdu Bio-Town fund (成都生物城基金): in August 2025 it led the several-hundred-million-yuan Pre-A round of Evolutionary Tide (演生潮), with Qiming, 元生创投 and Chengdu Science & Technology Investment co-leading . And in January 2026 it appeared as an existing shareholder continuing to back Zenitar's nearly RMB 600 million Series C, led by Temasek's 淡明资本 and Qiming . Beyond these deal roles, elsewhere's corpus does not cover the fund's background, size, or strategy.
AI-generated — may contain errors, please verify.
Coverage
New Forces Keep Coming｜5Y News Monthly
The big news from last month.
BlueRun Ventures-backed Zenitar closes nearly RMB 600 million Series C round | BlueRun Family
Build a closed-loop, iterative system spanning "target identification — molecular design — efficacy validation"
5Y News | Zai Ling Bio Completes Nearly RMB 600 Million Series C Financing
The funding will go toward global clinical development, pipeline expansion, and technology platform upgrades.
Qiming Venture Partners co-leads Zenitar's nearly 600 million yuan Series C round
late-stage clinical biotech company
Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads
Emergent Tide is built on original research from the Tsinghua University School of Medicine team in the field of humoral immunity, developing novel therapeutics for inflammatory and autoimmune diseases against a first-in-class global target, addressing core challenges in the field and significant unmet clinical needs.
